Back

WuXi Biologics named to Forbes China’s 2026 ESG 50 list

Verifying
  • WuXi Biologics joined Forbes China’s 2026 ESG 50 list for sustainability and ESG innovation.
  • WuXi Biologics cut Scope 1 and 2 emissions intensity 30% from 2020 levels.
  • Forbes China reviewed Chinese Forbes Global 2000 companies across environmental, social and governance practices.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.